vTv Therapeutics(US:VTVT)2024-11-12 21:26Financial Performance - Net loss attributable to vTv shareholders for Q3 2024 was $4.8 million, or $0.88 per basic share, an improvement from a net loss of $6.7 million, or $3.19 per basic share, in Q3 2023[2][4] - The company reported an operating loss of $6.5 million for Q3 2024, compared to an operating loss of $5.4 million in Q3 2023[4] - Other income for Q3 2024 was $0.2 million, compared to an expense of $3.3 million in Q3 2023, indicating a significant turnaround[2] Cash and Assets - Cash position increased to $41.6 million as of September 30, 2024, up from $9.4 million as of December 31, 2023[2] - Total current assets increased to $42.96 million as of September 30, 2024, compared to $10.66 million as of December 31, 2023[3] - Total liabilities decreased to $25.25 million as of September 30, 2024, down from $29.57 million as of December 31, 2023[3] Expenses - Research and Development (R&D) expenses for Q3 2024 were $3.2 million, compared to $2.8 million in Q3 2023, reflecting a 14.3% increase[2] - General and Administrative (G&A) expenses rose to $3.3 million in Q3 2024 from $2.5 million in Q3 2023, marking a 32% increase[2] Product Development - The company is progressing with the cadisegliatin program, aimed at improving glycemic control in type 1 diabetes patients, and is in discussions with the FDA regarding a clinical hold[1] - vTv Therapeutics is focused on developing oral, small molecule drug candidates, with cadisegliatin as a lead program for type 1 diabetes[5]